Skip to main content
Top
Published in: BMC Nephrology 1/2021

Open Access 01-12-2021 | Anemia | Research

Impact of the relationship between hemoglobin levels and renal interstitial fibrosis on long-term outcomes in type 2 diabetes with biopsy-proven diabetic nephropathy

Authors: Miho Shimizu, Kengo Furuichi, Shinji Kitajima, Tadashi Toyama, Megumi Oshima, Hisayuki Ogura, Koichi Sato, Shiori Nakagawa, Yuta Yamamura, Taro Miyagawa, Akinori Hara, Yasunori Iwata, Norihiko Sakai, Kiyoki Kitagawa, Mitsuhiro Yoshimura, Hitoshi Yokoyama, Takashi Wada

Published in: BMC Nephrology | Issue 1/2021

Login to get access

Abstract

Background

Progression of renal anemia has been shown to be associated with advanced renal tubulointerstitial lesions. This retrospective study investigated the impact of lower hemoglobin (Hb) levels and renal interstitial fibrosis and tubular atrophy (IFTA) on long-term outcomes in type 2 diabetes with biopsy-proven diabetic nephropathy.

Methods

A total of 233 patients were enrolled. The severity of IFTA was scored according to the classification by the Renal Pathology Society. Patients were stratified according to baseline Hb tertiles by IFTA status. The outcomes were the first occurrence of renal events (requirement for dialysis or 50 % decline in estimated glomerular filtration rate from baseline) and all-cause mortality.

Results

At baseline, 151 patients had severe IFTA. There were no patients who have been received erythropoiesis-stimulating agents at the time of renal biopsy. The severity of IFTA was the independent pathological factor of lower Hb levels. During the mean follow-up period of 8.6 years (maximum, 32.4 years), 119 renal events and 42 deaths were observed. Compared with the combined influence of the highest tertile of Hb and mild IFTA, the risks of renal events were higher for the middle tertile and for the lowest tertile of Hb in severe IFTA, whereas the risk of renal events was higher for the lowest tertile of Hb in mild IFTA. The risk of mortality was higher for the lowest tertile of Hb only in severe IFTA. There were significant interactions of tertile of Hb and IFTA in renal events and mortality.

Conclusions

Impacts of lower Hb levels on long-term outcomes of diabetic nephropathy were greater in severe IFTA than in mild IFTA.
Literature
1.
go back to reference Ritz E, Haxsen V. Diabetic nephropathy and anaemia. Eur J Clin Invest. 2005; 35(Suppl 3): 66–74.CrossRef Ritz E, Haxsen V. Diabetic nephropathy and anaemia. Eur J Clin Invest. 2005; 35(Suppl 3): 66–74.CrossRef
2.
go back to reference Mehdi U, Toto RD. Anemia, diabetes, and chronic kidney disease. Diabetes Care. 2009; 32(7): 1320–6.CrossRef Mehdi U, Toto RD. Anemia, diabetes, and chronic kidney disease. Diabetes Care. 2009; 32(7): 1320–6.CrossRef
3.
go back to reference Mise K, Hoshino T, Ueno T, et al. Impact of tubulointerstitial lesions on anaemia in patients with biopsy-proven diabetic nephropathy. Diabet Med. 2015; 32(4): 546–55.CrossRef Mise K, Hoshino T, Ueno T, et al. Impact of tubulointerstitial lesions on anaemia in patients with biopsy-proven diabetic nephropathy. Diabet Med. 2015; 32(4): 546–55.CrossRef
4.
go back to reference Tsuchimoto A, Masutani K, Haruyama N, et al. Renal interstitial fibrosis in 0-hour biopsy as a predictor of post-transplant anemia. Am J Nephrol. 2013; 38(4): 267–74.CrossRef Tsuchimoto A, Masutani K, Haruyama N, et al. Renal interstitial fibrosis in 0-hour biopsy as a predictor of post-transplant anemia. Am J Nephrol. 2013; 38(4): 267–74.CrossRef
5.
go back to reference Kawamura T, Usui J, Kaneko S, et al. Anaemia is an essential complication of ANCA-associated renal vasculitis: a single center cohort study. BMC Nephrol. 2017; 18(1): 337.CrossRef Kawamura T, Usui J, Kaneko S, et al. Anaemia is an essential complication of ANCA-associated renal vasculitis: a single center cohort study. BMC Nephrol. 2017; 18(1): 337.CrossRef
6.
go back to reference Tervaert TW, Mooyaart AL, Amann K, et al. Pathologic classification of diabetic nephropathy. J Am Soc Nephrol. 2010; 21(4), 556–63.CrossRef Tervaert TW, Mooyaart AL, Amann K, et al. Pathologic classification of diabetic nephropathy. J Am Soc Nephrol. 2010; 21(4), 556–63.CrossRef
7.
go back to reference Shimizu M, Furuichi K, Toyama T, et al. Long-term outcomes of Japanese type 2 diabetic patients with biopsy-proven diabetic nephropathy. Diabetes Care. 2013; 36(11): 3655–62.CrossRef Shimizu M, Furuichi K, Toyama T, et al. Long-term outcomes of Japanese type 2 diabetic patients with biopsy-proven diabetic nephropathy. Diabetes Care. 2013; 36(11): 3655–62.CrossRef
8.
go back to reference Furuichi K, Yuzawa Y, Shimizu M, et al. Nationwide multicentre kidney biopsy study of Japanese patients with type 2 diabetes. Nephrol Dial Transplant. 2018; 33(1): 138–48.CrossRef Furuichi K, Yuzawa Y, Shimizu M, et al. Nationwide multicentre kidney biopsy study of Japanese patients with type 2 diabetes. Nephrol Dial Transplant. 2018; 33(1): 138–48.CrossRef
9.
go back to reference Furuichi K, Shimizu M, Yuzawa Y, et al. Clinicopathological analysis of biopsy-proven diabetic nephropathy based on the Japanese classification of diabetic nephropathy. Clin Exp Nephrol. 2018; 22(3): 570–82.CrossRef Furuichi K, Shimizu M, Yuzawa Y, et al. Clinicopathological analysis of biopsy-proven diabetic nephropathy based on the Japanese classification of diabetic nephropathy. Clin Exp Nephrol. 2018; 22(3): 570–82.CrossRef
10.
go back to reference Yamanouchi M, Hoshino J, Ubara Y, et al. Value of adding the renal pathological score to the kidney failure risk equation in advanced diabetic nephropathy. PLoS One. 2018; 13(1): e0190930.CrossRef Yamanouchi M, Hoshino J, Ubara Y, et al. Value of adding the renal pathological score to the kidney failure risk equation in advanced diabetic nephropathy. PLoS One. 2018; 13(1): e0190930.CrossRef
11.
go back to reference Hoshino J, Furuichi K, Yamanouchi M, et al. A new pathological scoring system by the Japanese classification to predict renal outcome in diabetic nephropathy. PLoS One. 2018; 13(2): e0190923.CrossRef Hoshino J, Furuichi K, Yamanouchi M, et al. A new pathological scoring system by the Japanese classification to predict renal outcome in diabetic nephropathy. PLoS One. 2018; 13(2): e0190923.CrossRef
12.
go back to reference Yamanouchi M, Furuichi K, Hoshino J, et al. Nonproteinuric versus proteinuric phenotypes in diabetic kidney disease: A propensity score-matched analysis of a nationwide, biopsy-based cohort study. Diabetes Care. 2019; 42(5): 891–902.CrossRef Yamanouchi M, Furuichi K, Hoshino J, et al. Nonproteinuric versus proteinuric phenotypes in diabetic kidney disease: A propensity score-matched analysis of a nationwide, biopsy-based cohort study. Diabetes Care. 2019; 42(5): 891–902.CrossRef
13.
go back to reference Mise K, Hoshino J, Ueno T, et al. Clinical and pathological predictors of estimated GFR decline in patients with type 2 diabetes and overt proteinuric diabetic nephropathy. Diabetes Metab Res Rev. 2015; 31(6): 572–81.CrossRef Mise K, Hoshino J, Ueno T, et al. Clinical and pathological predictors of estimated GFR decline in patients with type 2 diabetes and overt proteinuric diabetic nephropathy. Diabetes Metab Res Rev. 2015; 31(6): 572–81.CrossRef
14.
go back to reference An Y, Xu F, Le W, et al. Renal histologic changes and the outcome in patients with diabetic nephropathy. Nephrol Dial Transplant. 2015; 30(2): 257–66.CrossRef An Y, Xu F, Le W, et al. Renal histologic changes and the outcome in patients with diabetic nephropathy. Nephrol Dial Transplant. 2015; 30(2): 257–66.CrossRef
15.
go back to reference Committee of the Japan Diabetes Society on the Diagnostic Criteria of Diabetes Mellitus. Report of the committee on the classification and diagnostic criteria of diabetes mellitus. J Diabetes Investig. 2010; 1(5): 212–28.CrossRef Committee of the Japan Diabetes Society on the Diagnostic Criteria of Diabetes Mellitus. Report of the committee on the classification and diagnostic criteria of diabetes mellitus. J Diabetes Investig. 2010; 1(5): 212–28.CrossRef
16.
go back to reference Matsuo S, Imai E, Horio M, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009; 53(6): 982–92.CrossRef Matsuo S, Imai E, Horio M, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009; 53(6): 982–92.CrossRef
17.
go back to reference Shimizu M, Furuichi K, Toyama T, et al. Association of renal arteriosclerosis and hypertension with renal and cardiovascular outcomes in Japanese type 2 diabetes patients with diabetic nephropathy. J Diabetes Investig. 2019; 10(4): 1041–9.CrossRef Shimizu M, Furuichi K, Toyama T, et al. Association of renal arteriosclerosis and hypertension with renal and cardiovascular outcomes in Japanese type 2 diabetes patients with diabetic nephropathy. J Diabetes Investig. 2019; 10(4): 1041–9.CrossRef
18.
go back to reference Shimizu M, Furuichi K, Yokoyama H, et al. Kidney lesions in diabetic patients with normoalbuminuric renal insufficiency. Clin Exp Nephrol. 2014; 18(2): 305–12.CrossRef Shimizu M, Furuichi K, Yokoyama H, et al. Kidney lesions in diabetic patients with normoalbuminuric renal insufficiency. Clin Exp Nephrol. 2014; 18(2): 305–12.CrossRef
19.
go back to reference Gellman DD, Pirani CL, Soothill JF, et al. Diabetic nephropathy: a clinical and pathologic study based on renal biopsies. Medicine (Baltimore). 1959; 38: 321–67.CrossRef Gellman DD, Pirani CL, Soothill JF, et al. Diabetic nephropathy: a clinical and pathologic study based on renal biopsies. Medicine (Baltimore). 1959; 38: 321–67.CrossRef
20.
go back to reference Takazakura E, Nakamoto Y, Hayakawa H, et al. Onset and progression of diabetic glomerulosclerosis; a prospective study based on serial renal biopsies. Diabetes. 1975; 24(1): 1–9.CrossRef Takazakura E, Nakamoto Y, Hayakawa H, et al. Onset and progression of diabetic glomerulosclerosis; a prospective study based on serial renal biopsies. Diabetes. 1975; 24(1): 1–9.CrossRef
21.
go back to reference Loeffler I, Wolf G. Mechanism of interstitial fibrosis in diabetic nepropahy. In: Joris J. Roelofs, Liffert Vogt, ed. Diabetic Nephropathy Pathophysiology and Clinical Aspects. Springer, New York: 2018; 227–51. Loeffler I, Wolf G. Mechanism of interstitial fibrosis in diabetic nepropahy. In: Joris J. Roelofs, Liffert Vogt, ed. Diabetic Nephropathy Pathophysiology and Clinical Aspects. Springer, New York: 2018; 227–51.
22.
go back to reference Iwano M, Neilson EG. Mechanisms of tubulointerstitial fibrosis. Curr Opin Nephrol Hypertens. 2004; 13(3): 279–84.CrossRef Iwano M, Neilson EG. Mechanisms of tubulointerstitial fibrosis. Curr Opin Nephrol Hypertens. 2004; 13(3): 279–84.CrossRef
23.
go back to reference Selby NM, Blankestijn PJ, Boor P, et al. Magnetic resonance imaging biomarkers for chronic kidney disease: a position paper from the European Cooperation in Science and Technology Action PARENCHIMA. Nephrol Dial Transplant. 2018; 33(suppl_2): ii4–ii14.CrossRef Selby NM, Blankestijn PJ, Boor P, et al. Magnetic resonance imaging biomarkers for chronic kidney disease: a position paper from the European Cooperation in Science and Technology Action PARENCHIMA. Nephrol Dial Transplant. 2018; 33(suppl_2): ii4–ii14.CrossRef
24.
go back to reference Caroli A, Schneider M, Friedli I, et al. Diffusion-weighted magnetic resonance imaging to assess diffuse renal pathology: a systematic review and statement paper. Nephrol Dial Transplant. 2018; 33(suppl_2): ii29–ii40.CrossRef Caroli A, Schneider M, Friedli I, et al. Diffusion-weighted magnetic resonance imaging to assess diffuse renal pathology: a systematic review and statement paper. Nephrol Dial Transplant. 2018; 33(suppl_2): ii29–ii40.CrossRef
25.
go back to reference Srivastava A, Cai X, Lee J, et al. Kidney functional magnetic resonance imaging and change in eGFR in individuals with CKD. Clin J Am Soc Nephrol. 2020; 15(6): 776–83.CrossRef Srivastava A, Cai X, Lee J, et al. Kidney functional magnetic resonance imaging and change in eGFR in individuals with CKD. Clin J Am Soc Nephrol. 2020; 15(6): 776–83.CrossRef
26.
go back to reference Fujita Y, Doi Y, Hamano T, et al. Low erythropoietin levels predict faster renal function decline in diabetic patients with anemia: a prospective cohort study. Sci Rep. 2019; 9(1): 14871.CrossRef Fujita Y, Doi Y, Hamano T, et al. Low erythropoietin levels predict faster renal function decline in diabetic patients with anemia: a prospective cohort study. Sci Rep. 2019; 9(1): 14871.CrossRef
27.
go back to reference Wakashima T, Tanaka T, Fukui K, et al. JTZ-951, an HIF prolyl hydroxylase inhibitor, suppresses renal interstitial fibroblast transformation and expression of fibrosis-related factors. Am J Physiol Renal Physiol. 2020; 318(1): F14–F24.CrossRef Wakashima T, Tanaka T, Fukui K, et al. JTZ-951, an HIF prolyl hydroxylase inhibitor, suppresses renal interstitial fibroblast transformation and expression of fibrosis-related factors. Am J Physiol Renal Physiol. 2020; 318(1): F14–F24.CrossRef
28.
go back to reference Wei X, Zhu X, Jiang L, et al. Recent advances in understanding the role of hypoxia-inducible factor 1α in renal fibrosis. Int Urol Nephrol. 2020; 52(7): 1287–95.CrossRef Wei X, Zhu X, Jiang L, et al. Recent advances in understanding the role of hypoxia-inducible factor 1α in renal fibrosis. Int Urol Nephrol. 2020; 52(7): 1287–95.CrossRef
29.
go back to reference Sano M, Takei M, Shiraishi Y, et al. Increased hematocrit during sodium-glucose cotransporter 2 inhibitor therapy indicates recovery of tubulointerstitial function in diabetic kidneys. J Clin Med Res. 2016; 8(12): 844–7.CrossRef Sano M, Takei M, Shiraishi Y, et al. Increased hematocrit during sodium-glucose cotransporter 2 inhibitor therapy indicates recovery of tubulointerstitial function in diabetic kidneys. J Clin Med Res. 2016; 8(12): 844–7.CrossRef
30.
go back to reference Marathias KP, Lambadiari VA, Markakis KP, et al. Competing effects of renin angiotensin system blockade and sodium-glucose cotransporter-2 inhibitors on erythropoietin secretion in diabetes. Am J Nephrol. 2020; 51(5): 349–56.CrossRef Marathias KP, Lambadiari VA, Markakis KP, et al. Competing effects of renin angiotensin system blockade and sodium-glucose cotransporter-2 inhibitors on erythropoietin secretion in diabetes. Am J Nephrol. 2020; 51(5): 349–56.CrossRef
31.
go back to reference Pappa M, Dounousi E, Duni A, et al. Less known pathophysiological mechanisms of anemia in patients with diabetic nephropathy. Int Urol Nephrol. 2015; 47(8): 1365–72.CrossRef Pappa M, Dounousi E, Duni A, et al. Less known pathophysiological mechanisms of anemia in patients with diabetic nephropathy. Int Urol Nephrol. 2015; 47(8): 1365–72.CrossRef
32.
go back to reference Hara A, Furuichi K, Koshino A, et al. Clinical and pathological significance of autoantibodies to erythropoietin receptor in type 2 diabetic patients with CKD. Kidney Int Rep. 2017; 3(1): 133–41.CrossRef Hara A, Furuichi K, Koshino A, et al. Clinical and pathological significance of autoantibodies to erythropoietin receptor in type 2 diabetic patients with CKD. Kidney Int Rep. 2017; 3(1): 133–41.CrossRef
Metadata
Title
Impact of the relationship between hemoglobin levels and renal interstitial fibrosis on long-term outcomes in type 2 diabetes with biopsy-proven diabetic nephropathy
Authors
Miho Shimizu
Kengo Furuichi
Shinji Kitajima
Tadashi Toyama
Megumi Oshima
Hisayuki Ogura
Koichi Sato
Shiori Nakagawa
Yuta Yamamura
Taro Miyagawa
Akinori Hara
Yasunori Iwata
Norihiko Sakai
Kiyoki Kitagawa
Mitsuhiro Yoshimura
Hitoshi Yokoyama
Takashi Wada
Publication date
01-12-2021
Publisher
BioMed Central
Published in
BMC Nephrology / Issue 1/2021
Electronic ISSN: 1471-2369
DOI
https://doi.org/10.1186/s12882-021-02510-y

Other articles of this Issue 1/2021

BMC Nephrology 1/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.